Broken MFN Clauses: SAFE Amendments and Orphan Rights
How SAFE amendment mechanics can create orphan MFN rights that blow up your Series A, and how to fix the paperwork before pricing.
A company raises a pre-seed on SAFEs from 18 angels and 3 micro-funds. Six months later, one investor asks for a side letter with pro rata rights and an information right. Another asks to update its SAFE to match a newer template. A third invokes MFN. Counsel circulates an amendment. Some investors sign immediately. Some email “looks fine” but never countersign. One fund says it elects only the valuation cap improvement, not the governance language. Another signed a side letter at the original close that nobody uploaded into the financing folder. Then the company grows fast, puts together a strong Series A, and sends diligence materials to the lead.
Two days later, the lead’s counsel asks the question founders hate: “Please provide a complete schedule of all SAFEs, side letters, MFN elections, amendments, joinders, and evidence of investor consent by instrument.”
What looked like harmless paperwork now becomes a deal issue. Not because the company gave away obviously crazy terms. Because the amendment mechanics were sloppy enough to create uncertainty about who actually has what rights.
That is the broken MFN trap.
The trap is not simply that MFN clauses can import investor-friendly economics. Sophisticated founders already know that. The deeper problem is that uneven amendments, partial elections, unsigned counters, inconsistent templates, and casual email-based “agreements” create orphan rights: rights that may exist for some holders, may have been elected by others, may have been partially adopted through MFN, and may not be fully documented in a way that lets a future lead or its counsel conclude with confidence that the pre-A stack is clean.
And uncertainty is expensive.
Series A leads do not experience cap table ambiguity as a clerical nuisance. They experience it as pricing risk, closing risk, and leverage risk. If they cannot tell whether 2, 7, or 14 SAFE holders have pro rata rights, information rights, board observer rights, discount protections, shadow preferred entitlements, or consent rights triggered in the next round, they will assume the worst until proven otherwise. That assumption can reduce your effective valuation, delay signing, increase legal fees, force pre-closing cleanup, or give the investor a basis to retrade economics.
This article is about how orphan rights emerge from process failures rather than obviously bad substantive terms, why Series A investors care so much, and how founders can run a practical amendment audit and cleanup before diligence weaponizes administrative sloppiness.
The real problem is not “bad SAFEs.” It is fragmented legal state.
Most founders frame SAFE risk the wrong way. They focus on the headline terms:
Those matter, but Series A diligence problems usually come from something more operational: your company has multiple overlapping legal states for similar instruments, and nobody can prove which state governs which investor.
That happens because startup financings are iterative. You do not issue one pristine set of documents in one closing to one coordinated syndicate. You issue instruments over time, often while the company is changing law firms, learning fundraising on the fly, and responding to investor-specific asks.
Typical sequence:
At that point, the company does not merely have “different investor terms.” It has a broken amendment architecture.
A broken amendment architecture creates orphan rights in three common ways:
1. Rights are granted but not validly attached across the full intended holder set
Example: the company wants to standardize pro rata rights for all SAFE holders above $250,000. Counsel sends a side letter amendment to 9 investors. Six sign. Two reply over email but never execute. One changes entity name and signs from the wrong vehicle. The company board deck later lists all 9 as having pro rata.
Result: three rights states exist simultaneously:
That third category is dangerous. It becomes “orphaned” from proper execution but still influences behavior and expectations.
2. Rights are elected through MFN in part, but the election mechanics are vague or incomplete
MFN sounds simple in founder conversations: “Existing SAFE holders can take better later terms.” In practice, MFN provisions often require actual election mechanics. Which later instrument counts? Can the investor cherry-pick only economics? Do side letters count? Are governance terms included? Must the company countersign the election? Was notice properly delivered?
If the investor says, “We elect the lower cap and related rights,” and the company never pushes back, what exactly migrated?
That is how rights become orphaned from a clear source document. The company cannot map the right to an executed instrument with precision, but the investor can plausibly claim it.
3. Counsel patch language across versions, creating silent divergence
This is extremely common. One SAFE form says amendments require the company and the investor. Another side letter says it binds successors and applies notwithstanding conflicting SAFE language. A later amendment says “all references to the SAFE shall be deemed updated.” Another says “except as otherwise provided herein.” A spreadsheet note says “investor on new terms.”
Founders assume these are equivalent cleanups. Series A counsel sees a chain-of-title problem for rights.
The issue is not just interpretation. The issue is enforceability under time pressure. If rights are spread across a SAFE, a side letter, two amendments, an email election, and a counsel summary that may or may not be operative, the company has to prove a coherent legal result. During a live round, that burden is painful.
Why current founder approaches fail
Most founder teams use one of three approaches to amendments and MFN management, and all three are inadequate once you are approaching an institutional round.
Approach 1: “The spreadsheet is the truth”
The finance lead or founder keeps a cap table tracker with columns like:
This is useful operationally and nearly worthless legally unless it is tied document-by-document to executed instruments and election evidence.
If your tracker says an investor has 1x pro rata, but the side letter was never countersigned, the tracker does not create the right. If the tracker says no observer rights, but the investor elected “all rights in the new SAFE” by notice under an MFN and nobody responded, the tracker does not eliminate the claim.
Spreadsheets summarize legal state; they do not establish it.
Approach 2: “Everyone was aligned commercially”
Founders often say some variation of: “Nobody was trying to play games. We all understood the deal.”
That is irrelevant in a priced round.
Series A counsel is not being difficult when they insist on signed consents and election support. Their job is to confirm exactly who can assert exactly which rights at closing and after closing. “Commercial understanding” collapses when a holder thinks it deserves super pro rata, a board observer seat, or a lower conversion price than reflected in the draft cap table.
Ambiguity becomes leverage the moment money is on the table.
Approach 3: “We’ll clean it up in the round”
This is the most dangerous approach because it misunderstands negotiating dynamics.
Founders assume pre-closing cleanup is a paperwork exercise. The lead treats unresolved cleanup as evidence of process weakness and latent stakeholder risk. If the company must chase 15 signatures while the term sheet clock is running, every missing signature becomes a mini holdout option.
A holder who invested $100,000 two years ago can suddenly extract attention disproportionate to its economics if its consent is needed or if its purported rights cloud closing certainty.
Even if the holder ultimately caves, the lead now knows your round can be delayed by clerical defects. That reduces your negotiating position.
What “orphan rights” actually look like in practice
Founders need a sharper definition. An orphan right is not just any investor right you regret. It is a right with one or more of the following properties:
Common orphan rights categories:
Not every orphan right is legally valid. That is exactly the problem. If the company cannot quickly show it is invalid, the right still creates transaction friction.
Why Series A leads treat broken MFN and amendment mechanics as a pricing issue
Founders often think this is purely a legal diligence matter. It is not. It directly affects price.
Here is how a Series A lead underwrites the risk.
1. The lead may not know true fully diluted ownership at closing
Suppose the company believes it has:
At a $40,000,000 pre-money Series A, the company models SAFE conversion as follows:
SAFE ownership % on a post-money basis = $4.0M / $20.0M = 20%
If the post-money SAFE stack is actually clean, then before the new money goes in, SAFE holders collectively own 20% of the company on the conversion basis defined by the instruments. Fine.
But now imagine that $1,500,000 of those SAFEs arguably elected via MFN into a lower $15,000,000 cap from a later issuance, and another $500,000 claims a 20% discount election from a side letter the company thought was investor-specific and non-electable. Suddenly the conversion stack may not be 20%.
Roughly:
Now the lead cannot trust the fully diluted denominator without instrument-by-instrument reconstruction. If the denominator may move, then the effective price per share and post-close ownership may move. That is a pricing issue, not just a document issue.
2. Governance overhang reduces round certainty
Imagine 4 investors may have board observer rights, but only 2 clearly do. Or 6 investors may have financing notice and participation rights that require procedural steps before the company can close a new round.
Even if these rights are economically minor, they can delay signing or closing if not handled properly. A lead will price that execution risk indirectly by demanding harder terms, longer exclusivity, a bigger option pool refresh, or simply a lower valuation to compensate for uncertainty.
3. Cleanup cost comes out of founder leverage
If the company must spend 3 to 5 weeks and $40,000 to $120,000 in legal fees reconstructing amendments, obtaining ratifications, and preparing disclosure schedules, that cost does not appear magically. It is paid either directly in fees or indirectly in momentum loss.
The round that looked competitive becomes a one-bid process because other investors move on while cleanup drags.
A concrete scenario: how a harmless MFN mismatch becomes a Series A headache
Let’s run a realistic example.
Seed-stage history
The company raises the following pre-Series A instruments:
What the company thinks it has
What Series A counsel sees
Potentially:
That is not a single rights state. That is multiple competing rights states.
Series A impact
Assume the company now raises a $12M Series A at a $36M pre-money valuation.
If all $2.8M SAFEs convert at a $10M cap equivalent, their aggregate pre-round ownership burden is much heavier than if $1.5M remains at $12M. Depending on the SAFE mechanics, the difference can move founder dilution materially.
Illustrative simplification:
That 2.5-point swing before the Series A is not trivial. On a $36M pre-money, it meaningfully changes who owns what.
Then add pro rata claims. If A, C, and D clearly have pro rata, and B plausibly claims it too, the lead must model not only conversion dilution but also who can participate to maintain ownership. If some of these rights are uncapped or ambiguously drafted, allocation in the round becomes harder.
The lead’s response is predictable:
Term sheet comparisons: where orphan rights show up in the Series A negotiation
Broken amendment mechanics rarely appear as a standalone term sheet line that says “discount for sloppy SAFE administration.” Instead they surface through adjacent asks.
Clean company scenario
Lead offers:
Broken MFN/orphan-rights scenario
Lead offers:
On paper, the lead did not say, “We are charging you 6 turns because your MFN process is sloppy.” In reality, that is exactly what happened.
The extra 2% option pool alone can be expensive. If the pre-money is also cut by $6M, the founder economics hit is real.
Quick math on the valuation retrade
Suppose before the term sheet the founders expected:
After diligence concerns:
That difference alone increases dilution by 2.2 points to founders and all pre-money holders, before considering a larger option pool.
If the lead also pushes the pool from 10% to 12% post-close, founders can easily lose several additional percentage points in effective ownership.
Administrative ambiguity just became economic pain.
The most misunderstood issue: MFN does not administer itself
Founders and even some junior operators treat MFN as if it automatically harmonizes terms. It does not. MFN is a mechanism that must be exercised, documented, and interpreted.
Key questions that determine whether rights become orphaned:
If your company cannot answer these questions investor-by-investor with document support, you do not have an MFN program. You have a dispute incubator.
How to run an amendment audit before the Series A process starts
This is the founder playbook. Do it before you launch the round, not during exclusivity.
Step 1: Build the instrument ledger, not just the cap table
Create a master ledger with one row per instrument and side agreement, not one row per investor summary.
For each investor, list:
Your goal is to create a chain-of-operability, not just economics.
Step 2: Create a rights matrix from documents only
Separate what is documented from what is assumed.
Columns should include:
Then use color coding:
This exercise alone usually surfaces 80% of the problem.
Step 3: Reconstruct MFN elections precisely
For every investor with MFN:
Do not accept shorthand like “Investor X matched the Horizon terms.” That phrase is exactly how orphan rights survive. Write the result with specificity:
“Investor X delivered election notice dated March 4, 2024 referencing SAFE D. Notice expressly elected reduced valuation cap only. No reference to side letter. No company countersignature required under clause. Therefore pro rata rights did not migrate.”
That level of precision is what diligence requires.
Step 4: Identify defects by category
Not every issue deserves the same fix.
Categories:
Different defect, different response.
How to run consent cleanup without creating new problems
Once you identify orphan-rights risk, the instinct is to paper everything immediately. Be careful. Cleanup itself can create leverage if handled clumsily.
Principle 1: Standardize, do not renegotiate where possible
Your first objective is not to ask every investor what they think they deserve. That invites reopening economics.
Instead, prepare a company-side proposed schedule that states the company’s determination of each investor’s operative rights and asks the investor to confirm or execute corrective documentation consistent with that schedule.
That changes the frame from open-ended negotiation to clerical ratification.
Principle 2: Use a single coherent amendment architecture
Do not patch a messy stack with five more bilateral side letters if one omnibus ratification and confirmation agreement can work.
Depending on counsel’s advice, a cleaner solution is often:
You want a closing binder that a future investor can read without archaeology.
Principle 3: Do not accidentally broaden MFN through cleanup language
This is a common own-goal.
Suppose you send an amendment saying: “Investor shall have terms no less favorable than those granted to Horizon Micro under the financing documents.” That may inadvertently import not just cap economics but also side-letter rights, future amendments, or procedural protections you did not intend.
Cleanup language should narrow uncertainty, not recreate it.
Principle 4: Distinguish confirmation from concession
If an investor never validly obtained pro rata rights, asking them to sign a confirmation agreement that now expressly grants pro rata is not cleanup. It is a concession.
Sometimes making that concession is worth it to clear the round. But call it what it is, price it consciously, and understand the precedent.
A practical negotiation scenario: one ambiguous investor can distort the round
Assume your lead is ready to sign at $45M pre, but diligence flags Investor B from the earlier example.
Investor B put in $250,000 on a $12M SAFE. It emailed “We’d like same economics” after Horizon’s $10M SAFE and pro rata side letter, but never signed either amendment or election. Your tracker nevertheless shows B at $10M and pro rata.
The lead asks for certainty. Your counsel says B likely has no documented pro rata and may still be at $12M, but there is some risk because the company’s internal communications and update emails treated B as included.
Now three paths exist:
Path A: Hardline legal position
Company tells B:
Upside: preserves economics if B signs.
Downside: B may resist, go silent, or ask for consideration.
Path B: Commercial compromise
Company offers:
Upside: likely faster.
Downside: some additional dilution versus company’s preferred position.
Path C: Full concession for speed
Company offers:
n- standard pro rata side letter
Upside: fastest cleanup.
Downside: now B got an upgrade because your paperwork was sloppy, and other holders may ask to revisit their own rights if they hear about it.
Founders often choose Path C under time pressure. Sometimes that is rational. But understand the cost.
Illustrative dilution math on the cap concession alone:
Difference between B at $12M and $10M cap on $250,000 principal:
Incremental burden = 0.42 percentage points before the Series A.
That sounds small. Multiply that by several investors and combine with pro rata rights, and the leakage becomes material.
What Series A counsel wants to see
If you want diligence to go smoothly, prepare the package they wish every startup had.
Minimum clean package
Ideal package
Add:
This is not overkill. This is valuation protection.
The founder protocol: how to avoid creating orphan rights going forward
The best cleanup is prevention.
1. One template family, version controlled
If you change SAFE forms or side-letter packages, record the reason and exactly who gets the new version. Avoid ad hoc redlines unless absolutely necessary.
2. No “email acceptance” for material rights changes
If a right matters enough to discuss, it matters enough to execute properly. Email sentiment is not a substitute for signed paper.
3. Formal MFN election procedures
Use a standard election form that requires the investor to specify:
If your existing clause does not require this, still operationalize it internally.
4. Update legal ledger and cap table software together
No rights status should appear in Carta, Pulley, or your internal tracker unless the supporting document is linked and reviewed.
5. Quarterly financing hygiene review
If you have more than a handful of SAFEs or any bespoke side letters, review the financing stack quarterly. It is vastly cheaper than emergency cleanup.
The hard truth founders should internalize
Series A leads do not punish you for having raised on SAFEs. They punish uncertainty.
A company can survive investor-friendly terms if those terms are clear, modeled, and documentable. What investors hate is a financing stack where no one knows which rights are real until someone gets upset.
That is why broken MFN mechanics are so dangerous. They create latent optionality for old investors and immediate uncertainty for new investors. Old investors may never assert the rights, until the leverage of a new round gives them reason to. New investors may never be harmed by those rights, unless they cannot get comfortable enough to close without changing the deal.
Founders often think the risk is legal enforceability in the abstract. The real risk is practical exploitability during a live financing.
If a right is ambiguous, it can still delay closing.
If a consent is missing, it can still trigger a cleanup demand.
If an election was sloppy, it can still move dilution assumptions.
If your own tracker overstates rights, it can still undermine your negotiating credibility.
That is what blows up rounds: not dramatic fraud, but messy legal state colliding with institutional diligence.
Final takeaways
The companies that handle this well are not the ones with perfect fundraising histories. They are the ones that understand a simple rule: in venture financing, ambiguity is a form of dilution. Maybe not immediately on the cap table, but certainly in the negotiation.
If you have more than a few SAFEs, any side letters, or any investor ever told you “just put us on the same terms as the last guy,” run the amendment audit now. Do it before a lead investor’s counsel does it for you, on a deadline, with your valuation open on the table.
RaiseSimpli Team
Author